Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.

Earlier Friday, Hikma noted its Generics business has experienced some headwinds. Hikma explained its Generics business has been hurt by increased competition and a challenging pricing environment, resulting in a ‘slow’ start to the year. Conversely, Hikma reported its Branded business is performing well.

Current stock price: 1,883.50 pence

12-month change: down 22%

Copyright 2022 Alliance News Limited. All Rights Reserved.